What service do you need? Contact Request

NCT05568095

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

← Hub

Registry fields

Overall status: COMPLETED
Conditions: Advanced Upper Gastrointestinal Tract Adenocarcinoma
Study type: INTERVENTIONAL
Phase: PHASE3
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: Domvanalimab, Zimberelimab, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab
Lead sponsor: Arcus Biosciences, Inc. (INDUSTRY)

Cached at: 2026-09-04 00:21:23

View on ClinicalTrials.gov

Brief summary

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, and multiagent chemotherapy versus the anti PD-1 monoclonal antibody nivolumab and multiagent chemotherapy in the first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report